The future of plague vaccines: Hopes raised by a surrogate, live-attenuated recombinant vaccine candidate

Jason A. Rosenzweig, Ashok Chopra

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Yersinia pestis (YP) is the Gram-negative etiological agent of plague against which no commercial vaccine exists to prophylactically prevent a potential outbreak due to natural or bio-warfare/terrorism-mediated causes. The US FDA only recently approved levofloxacin to combat this deadly pathogen. In the article under review, an attenuated, recombinant Salmonella typhimurium ΔphoPQ mutant strain producing YP antigens F1, LcrV and F1-V (fusion protein) from either low-copy pBR or high-copy pUC vectors (maintained by plasmid addiction rather than antibiotic selection pressure) were evaluated for their ability to induce a humoral immune response in both mice and rabbits. This study highlights the need for developing a well-tolerated YP vaccine that, through the oral route, can be readily administered and elicit both mucosal and systemic anti-plague humoral immunity.

Original languageEnglish (US)
Pages (from-to)659-661
Number of pages3
JournalExpert Review of Vaccines
Volume11
Issue number6
DOIs
StatePublished - Jun 2012

Fingerprint

Plague Vaccine
Yersinia pestis
Attenuated Vaccines
Synthetic Vaccines
Plague
Humoral Immunity
Vaccines
Terrorism
Levofloxacin
Salmonella typhimurium
Disease Outbreaks
Plasmids
Anti-Bacterial Agents
Rabbits
Pressure
Proteins

Keywords

  • balanced lethal plasmids
  • F1
  • LcrV antigen
  • Salmonella typhimurium-attenuated ΔphoP/Q mutant
  • Yersinia pestis vaccine

ASJC Scopus subject areas

  • Immunology
  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Cite this

The future of plague vaccines : Hopes raised by a surrogate, live-attenuated recombinant vaccine candidate. / Rosenzweig, Jason A.; Chopra, Ashok.

In: Expert Review of Vaccines, Vol. 11, No. 6, 06.2012, p. 659-661.

Research output: Contribution to journalArticle

@article{32a13c1b64894e708e741804e90eaf1d,
title = "The future of plague vaccines: Hopes raised by a surrogate, live-attenuated recombinant vaccine candidate",
abstract = "Yersinia pestis (YP) is the Gram-negative etiological agent of plague against which no commercial vaccine exists to prophylactically prevent a potential outbreak due to natural or bio-warfare/terrorism-mediated causes. The US FDA only recently approved levofloxacin to combat this deadly pathogen. In the article under review, an attenuated, recombinant Salmonella typhimurium ΔphoPQ mutant strain producing YP antigens F1, LcrV and F1-V (fusion protein) from either low-copy pBR or high-copy pUC vectors (maintained by plasmid addiction rather than antibiotic selection pressure) were evaluated for their ability to induce a humoral immune response in both mice and rabbits. This study highlights the need for developing a well-tolerated YP vaccine that, through the oral route, can be readily administered and elicit both mucosal and systemic anti-plague humoral immunity.",
keywords = "balanced lethal plasmids, F1, LcrV antigen, Salmonella typhimurium-attenuated ΔphoP/Q mutant, Yersinia pestis vaccine",
author = "Rosenzweig, {Jason A.} and Ashok Chopra",
year = "2012",
month = "6",
doi = "10.1586/erv.12.34",
language = "English (US)",
volume = "11",
pages = "659--661",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - The future of plague vaccines

T2 - Hopes raised by a surrogate, live-attenuated recombinant vaccine candidate

AU - Rosenzweig, Jason A.

AU - Chopra, Ashok

PY - 2012/6

Y1 - 2012/6

N2 - Yersinia pestis (YP) is the Gram-negative etiological agent of plague against which no commercial vaccine exists to prophylactically prevent a potential outbreak due to natural or bio-warfare/terrorism-mediated causes. The US FDA only recently approved levofloxacin to combat this deadly pathogen. In the article under review, an attenuated, recombinant Salmonella typhimurium ΔphoPQ mutant strain producing YP antigens F1, LcrV and F1-V (fusion protein) from either low-copy pBR or high-copy pUC vectors (maintained by plasmid addiction rather than antibiotic selection pressure) were evaluated for their ability to induce a humoral immune response in both mice and rabbits. This study highlights the need for developing a well-tolerated YP vaccine that, through the oral route, can be readily administered and elicit both mucosal and systemic anti-plague humoral immunity.

AB - Yersinia pestis (YP) is the Gram-negative etiological agent of plague against which no commercial vaccine exists to prophylactically prevent a potential outbreak due to natural or bio-warfare/terrorism-mediated causes. The US FDA only recently approved levofloxacin to combat this deadly pathogen. In the article under review, an attenuated, recombinant Salmonella typhimurium ΔphoPQ mutant strain producing YP antigens F1, LcrV and F1-V (fusion protein) from either low-copy pBR or high-copy pUC vectors (maintained by plasmid addiction rather than antibiotic selection pressure) were evaluated for their ability to induce a humoral immune response in both mice and rabbits. This study highlights the need for developing a well-tolerated YP vaccine that, through the oral route, can be readily administered and elicit both mucosal and systemic anti-plague humoral immunity.

KW - balanced lethal plasmids

KW - F1

KW - LcrV antigen

KW - Salmonella typhimurium-attenuated ΔphoP/Q mutant

KW - Yersinia pestis vaccine

UR - http://www.scopus.com/inward/record.url?scp=84864927784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864927784&partnerID=8YFLogxK

U2 - 10.1586/erv.12.34

DO - 10.1586/erv.12.34

M3 - Article

C2 - 22873124

AN - SCOPUS:84864927784

VL - 11

SP - 659

EP - 661

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 6

ER -